Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of IPO & Placements for Aequitas Research. At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%. 
Prior to Aequitas. I was heading Content Strategy for Smartkarma, along with covering IPOs & Placement. In an earlier life I have covered ASEAN property and the banking space in India.

Head of Research, IPOs & Placements

Hindustan Unilever | Potential Estimates and Valuations | #Comebackstronger

Hindustan Unilever - Overhang Gone, Now Comes The Passive Flow

Hindustan Unilever Rally Support into Bigger Top Cycle

Hindustan Unilever Prospective Placement - Early Look - The US$3.6bn Overhang

HUVR Vs ITC | The Dancing Elephant and the Ostrich

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Hindustan Unilever / Equity Capital Markets

<div><p>In my insight earlier this week, <a href="https://www.smartkarma.com/insights/hindustan-unilever-prospective-placement-early-look-the-us-3-6bn-overhang" target="_blank" rel="noopener">Hindustan Unilever Prospective Placement - Early Look - The US$3.6bn Overhang</a>, I wrote about how <a href="https://www.smartkarma.com/entities/glaxosmithkline-plc" target="_blank" data-smartkarma-citation="entities:21960:1" rel="noopener">GlaxoSmithKline PLC (GSK LN)</a> owns about 5.7% of <a href="https://www.smartkarma.com/entities/hindustan-unilever-ltd" target="_blank" data-smartkarma-citation="entities:13828:1" rel="noopener">Hindustan Unilever (HUVR IN)</a>, which it needs to sell.</p></div><div><p>Thus, the deal is expected and well flagged. GSK has rightfully chosen to exit in one shot, removing any further overhang on HUL. </p></div>

In my insight earlier this week, Hindustan Unilever Prospective Placement - Early Look - The US$3.6bn Overhang, I wrote about how GlaxoSmithKline PLC (GSK LN) owns about 5.7% of Hindustan Unilever (HUVR IN), which it needs to sell.Thus, the deal is expected and well flagged. GSK has rightfully chosen to exit in one shot, removing any further overhang on HUL. 

Hindustan Unilever 배치 - 예상대로, 제대로 수행